The MSIA has defended the administration's decision not to identify eight digital scribes potentially subject to medical device regulation, warning that naming developers before assessing safety or performance could be prejudicial.
The MSIA has defended the administration’s decision not to identify eight digital scribes potentially subject to medical device regulation, warning that naming developers before assessing safety or performance could be prejudicial.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.